Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

Nature Medicine published the phase 2 MDT-BRIDGE trial, which studied neoadjuvant durvalumab plus chemotherapy in patients with resectable or borderline resectable non-small-cell lung cancer. No trial results are provided in the available context.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.